Our Company

1-10 of 30

Prevalence, treatments and medical cost of multiple sclerosis in Japan based on analysis of a health insurance claims database26 September 2017 - By Hiroyuki Ohta and Izumi Kawachi and Manami Yoshida and Mariko Sakamoto and Mieko Ogino and Shinzo Hiroi and Shuichi Okamoto and Kosuke Iwasaki - Article

This article analyzes health insurance claims data to determine the current treatment status and medical cost of multiple sclerosis in Japan.

Analysis of second- and third-line antihypertensive treatments after initial therapy with an angiotensin II receptor blocker using real-world Japanese data01 August 2016 - By Mitsuru Ohishi and Shinzo Hiroi and Takashi Kikuchi and Yukio Shimasaki and Kosuke Iwasaki and Yujiro Otsuka - Article

This study examines combination therapies administered following initial therapy with an angiotensin II receptor blocker in hyperintensive Japanese patients.

Current treatment status and medical cost for multiple sclerosis based on analysis of a Japanese claims database04 April 2016 - By Hiroyuki Ohta and Izumi Kawachi and Kazuyoshi Otake and Mieko Ogino and Shinzo Hiroi and Kosuke Iwasaki and Yujiro Otsuka - Article

This study provides up-to-date information on the demographics, medical treatment and cost status of multiple sclerosis treatment in Japan in almost real-time by using a claims database.

An actuarial study of hemophilia: Implications for commercial and Medicaid managed care plans05 March 2014 - By Melissa Fredericks and Bruce S. Pyenson and Kosuke Iwasaki - Article

This paper discusses the financial risks associated with hemophilia and outlines the issues for regulators, insurers, and provider organizations financially managing the care for this and other rare and expensive medical conditions.

Healthcare reform and hepatitis C: A convergence of risk and opportunity19 December 2013 - By Bruce S. Pyenson and Kathryn V. Fitch and Kosuke Iwasaki and Tyler Engel - Article

How will newly diagnosed or previously uninsured individuals with hepatitis C affect the U.S. healthcare system?

Comparing episode of cancer care costs in different settings: An actuarial analysis of patients receiving chemotherapy09 October 2013 - By Bruce S. Pyenson and Kathryn V. Fitch and Kosuke Iwasaki - Article

Chemotherapy treatment in hospital outpatient settings vs. in physicians offices in on the rise and increasing costs.

The incidence rate and economic burden of community-acquired pneumonia in a working-age population01 September 2013 - By Holly Yu and Reiko Sato and Bruce S. Pyenson and Jonah Broulette and Kosuke Iwasaki - Article

What is the economic impact of community-acquired pneumonia (CAP) in the employed population?

Major depressive disorder: An actuarial commercial claim data analysis31 July 2013 - By Kathryn V. Fitch and Kosuke Iwasaki - Article

Evaluating antidepressant formulary access and benefit design should help support effective antidepressant treatments in patients with major depressive disorder.

An actuarial analysis of treatment resistance in patients with major depressive disorder in a commercially insured population03 January 2013 - By Bruce S. Pyenson and Kathryn V. Fitch and Kosuke Iwasaki - Article
How does treatment resistance affect costs among patients with Major Depressive Disorder?National burden of preventable adverse drug events associated with inpatient injectable medications: Healthcare and medical professional liability costs10 December 2012 - By Betsy J. Lahue and Jeffrey M. Rothschild and Bruce S. Pyenson and Kosuke Iwasaki and Susan J. Forray - Article

What is the medical professional liability cost associated with preventable adverse drug effects?


  • Work at Milliman

    • “I was offered a chance to come in, shake things up, create something."
    Work at Milliman